FDA Approves Satralizumab for Thyroid Eye Disease. One of Two Phase 3 Trials Missed Its Primary Endpoint.
Enspryng, approved Oct. 15, is the first subcutaneous thyroid eye disease treatment patients can inject at home. In SatraGO-2, 52.9 percent had a proptosis response versus 23.4 percent with placebo; SatraGO-1 missed its endpoint.
The Food and Drug Administration approved satralizumab-mwge (Enspryng, Genentech/Roche) for adults with thyroid eye disease on Oct. 15, based on two phase 3 trials, one of which missed its primary endpoint.
The approval appears as an Oct. 15 supplement action in the FDA's Drugs@FDA database; Roche announced it from Basel the next day, which is why some coverage dates it Oct. 16. The updated label indicates Enspryng for thyroid eye disease regardless of disease activity or duration. Enspryng, an interleukin-6 receptor antagonist already approved for neuromyelitis optica spectrum disorder (NMOSD), is the first subcutaneous treatment for the condition that patients or caregivers can give at home after training, Roche said. It is the third FDA-approved therapy for thyroid eye disease, after teprotumumab (Tepezza) and veligrotug (Lumvoa), Healio reported.
What did the SatraGO trials show?
One trial was positive and one was not. SatraGO-1 and SatraGO-2 were identical randomized, double-masked, placebo-controlled phase 3 trials that enrolled 258 patients in 19 countries, about three-quarters with active, moderate-to-severe disease. The primary endpoint was the proptosis responder rate, a reduction of at least 2 mm in the study eye, at Week 24 in active disease.
In SatraGO-2, 52.9 percent of patients on Enspryng responded versus 23.4 percent on placebo, a difference of 28.9 percentage points (95% CI, 11.5 to 46.2), according to the prescribing information. In SatraGO-1, the rates were 49.0 percent versus 31.2 percent, a difference of 17.9 points (95% CI, -1.6 to 37.3; P=0.07), which did not meet the endpoint. In SatraGO-2, diplopia improved in 60.7 percent versus 25.8 percent of active-disease patients with diplopia at baseline, and the overall-population proptosis response, including inactive disease, was 46.9 percent versus 22.2 percent.
One positive and one negative pivotal trial is a thinner evidence base than a broad label suggests, and the inactive-disease group was less than a quarter of the patients studied.
How is it dosed, and what does the label warn about?
Dosing is by weight: 120 mg for patients 40 to 100 kg and 180 mg above 100 kg, given subcutaneously at Weeks 0, 2 and 4, then every four weeks from Week 8, per the label. Hepatitis B, tuberculosis and liver transaminase screening is required before the first dose, and active hepatitis B is a contraindication. Warnings cover infections, elevated liver enzymes, decreased neutrophil counts and hypersensitivity reactions.
In the pooled thyroid eye disease trials, upper respiratory tract infection (5.3 percent versus 2.4 percent) and increased alanine aminotransferase (5.3 percent versus 0.8 percent) were more common than with placebo. Roche said the safety profile was consistent with what is known from NMOSD.
What it means in clinic
For endocrinologists and primary care physicians, the practical change is a referral and monitoring question. Thyroid eye disease is usually managed with ophthalmology or oculoplastic input, and an at-home injection may suit patients who cannot travel for infusions, but the label's screening and liver monitoring requirements still need an owner.
Before the first patient asks, decide who in your referral network will document disease activity and proptosis at baseline, and who will order the pre-treatment labs. Pricing was not disclosed in the coverage reviewed, so payer rules are the next hurdle; prior authorization is likely to shape how often this drug is used.
Reported, fact-checked and edited by The Script Pad's editorial staff.
This article is for professional education and does not replace clinical judgment. Treatment decisions should be based on the individual patient and current guidelines.
